Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05020769
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center (SYSUCC), Guangdong, Guangzhou, China
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05017025
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT05011487
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 90
- Registration Number
- NCT04988607
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04959981
- Locations
- 🇺🇸
Hackensack University Medical Center (John Theurer Cancer Center), Hackensack, New Jersey, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Research Institute, Boston, Massachusetts, United States
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT04908956
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Sinchon-dong, Korea, Republic of
🇪🇸Hospital General de Alicante, Alicante, Spain
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 232
- Registration Number
- NCT04870190
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 576
- Registration Number
- NCT04868877
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori Regina Elena, Roma, Rome, Italy
🇮🇹Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy
🇺🇸START Mountain Region, West Valley City, Utah, United States
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 190
- Registration Number
- NCT04862780
- Locations
- 🇫🇷
Institut Claudius Regaud (IUCT-O) - Cancer Comprehensive Center, Toulouse, France
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇯🇵National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
- Conditions
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 88
- Registration Number
- NCT04829019
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.